References
- Dickens JA, Lomas DA. Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis. Drug Des Devel Ther. 2011;5:391–405.
- Lara B, Miravitlles M. Spanish registry of patients with alpha-1 antitrypsin deficiency; comparison of the characteristics of PISZ and PIZZ individuals. COPD. 2015;12:27–31. doi:https://doi.org/10.3109/15412555.2015.1021912.
- Mattman A, Gilfix BM, Chen SX, DeMarco ML, Kyle BD, Parker ML, Agbor TA, Jung B, Selvarajah S, Barakauskas VE, et al. Alpha-1-antitrypsin molecular testing in Canada: a seven year, multi-centre comparison. Clin Biochem. 2020;81:27–33. doi:https://doi.org/10.1016/j.clinbiochem.2020.05.001.
- Callea F, Giovannoni I, Francalanci P, Boldrini R, Faa G, Medicina D, Nobili V, Desmet VJ, Ishak K, Seyama K, et al. Mineralization of alpha-1-antitrypsin inclusion bodies in Mmalton alpha-1-antitrypsin deficiency. Orphanet J Rare Dis. 2018;13(1):79. doi:https://doi.org/10.1186/s13023-018-0821-7.
- Suárez-Lorenzo I, de Castro FR, Cruz-Niesvaara D, Herrera-Ramos E, Rodríguez-Gallego C, Carrillo-Diaz T. Alpha 1 antitrypsin distribution in an allergic asthmatic population sensitized to house dust mites. Clin Transl Allergy. 2018;8:44. doi:https://doi.org/10.1186/s13601-018-0231-x.
- Orrù G, Faa G, Pillai S, Pilloni L, Montaldo C, Pusceddu G, Piras V, Coni P. Rapid PCR real-time genotyping of M-Malton alpha1-antitrypsin deficiency alleles by molecular beacons. Diagn Mol Pathol. 2005;14(4):237–242. doi:https://doi.org/10.1097/01.pas.0000178221.44474.b3.
- de Serres FJ, Blanco I. Prevalence of α1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Ther Adv Respir Dis. 2012;6(5):277–295. doi:https://doi.org/10.1177/1753465812457113.
- Figueira Gonçalves JM, Martínez Bugallo F, Díaz Pérez D, Martín Martínez MD, García-Talavera I. Alpha-1 antitrypsin deficiency associated with the Mmalton variant. Description of a family. Arch Bronconeumol. 2016;52(12):617–618. doi:https://doi.org/10.1016/j.arbres.2016.05.005.
- Kueppers F, Sanders C. State-of-the-art testing for alpha-1 antitrypsin deficiency. Allergy Asthma Proc. 2017;38(2):108–114. doi:https://doi.org/10.2500/aap.2017.38.4031.
- Belmonte I, Barrecheguren M, López-Martínez RM, Esquinas C, Rodríguez E, Miravitlles M, Rodríguez-Frías F. Application of a diagnostic algorithm for the rare deficient variant Mmalton of alpha-1-antitrypsin deficiency: a new approach. Int J Chron Obstruct Pulmon Dis. 2016;11:2535–2541. doi:https://doi.org/10.2147/COPD.S115940.
- Joly P, Guillaud O, Hervieu V, Francina A, Mornex J-F, Chapuis-Cellier C. Clinical heterogeneity and potential high pathogenicity of the Mmalton Alpha 1 antitrypsin allele at the homozygous, compound heterozygous and heterozygous states. Orphanet J Rare Dis. 2015;10(1). [Internet]. [cited 2018 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596512/ doi:https://doi.org/10.1186/s13023-015-0350-6.
- Figueira Gonçalves JM, Martínez Bugallo F, Díaz Pérez D, Martín Martínez MD, García-Talavera I, Pitti Pérez R. Clinical manifestations of the Mmalton alpha-1 antitrypsin deficiency variant. Pulmonology. 2017;24(1):48–49. doi:https://doi.org/10.1016/j.rppnen.2017.11.004.